Non-obstructive Plaque and Treatment of INOCA: More to Be Learned
Lina Ya'Qoub1, Islam Y Elgendy2, Carl J Pepine3
1Division of Interventional Cardiology, Henry Ford Hospital, Detroit, MI, USA.
Insights
Ischemia with non-obstructive coronary artery disease (INOCA) affects many patients with chest pain. Stratified medical therapy shows promise in improving INOCA patient outcomes and quality of life.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Ischemia with non-obstructive coronary artery disease (INOCA) is diagnosed in a significant number of patients presenting with chest pain.
- INOCA is linked to a higher risk of major adverse cardiac events and poses a substantial burden on healthcare systems.
Purpose of the Study:
- To review the current understanding of INOCA, including its definition, epidemiology, pathophysiology, and management.
- To highlight recent findings and ongoing clinical trials investigating INOCA.
Main Methods:
- Review of existing scientific literature and clinical trial data.
- Discussion of findings from the CorMicA trial regarding stratified medical therapy for INOCA.
Main Results:
- The CorMicA trial demonstrated that stratified medical therapy improves symptoms and quality of life in INOCA patients.
- Ongoing trials like the WARRIOR trial are evaluating intensive medical therapy versus usual care for INOCA.
Conclusions:
- While evidence on INOCA management is evolving, stratified medical therapy is a promising approach.
- Further research and ongoing clinical trials are crucial for optimizing the care of patients with INOCA.
Purpose Of Review:
A significant proportion of patients evaluated for chest pain have ischemia with non-obstructive coronary artery disease (INOCA). Studies have shown INOCA is associated with increased risk of major adverse cardiac events and significant burden on the health care system.
Recent Findings:
While there is scarce scientific evidence on management of INOCA, the CorMicA trial showed that stratified medical therapy based on the type of INOCA improved patients' symptoms and quality of life. There are multiple ongoing trials, including Women's IschemiA Trial to Reduce Events in Non-ObstRuctIve CORonary Artery Disease (WARRIOR trial), assessing the benefit of intensive medical therapy versus usual care for this increasingly recognized clinical entity. In this review, we discuss the definition of INOCA, epidemiology and risk factors, pathophysiology, and management as well as the current knowledge gaps and ongoing clinical trials in this arena.
More Related Videos
09:43In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis
Published on: August 4, 2011
09:46Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
Related Concept Videos
Atherosclerosis I: Introduction
Atherosclerosis III: Management
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
